Background
==========

Esophageal cancer is a common cancer worldwide. GLOBOCAN 2018 reported the global incidence of esophageal cancer was 3.2% among 35 major cancers. Esophageal cancer, ranking as the ninth most common cancer, resulted in around 5.3% of all cancer-related deaths \[[@b1-medscimonit-25-9416]\]. Patients at the advanced stage, especially those with distant metastases, showed a significantly shorter survival \[[@b2-medscimonit-25-9416]\]. Thus, longer survival can be expected in patients who are diagnosed in the early stage.

Bone is a common organ for distant metastasis \[[@b3-medscimonit-25-9416],[@b4-medscimonit-25-9416]\]. In patients with esophageal cancer, bone metastasis (BM) was reported as the third common metastatic site \[[@b5-medscimonit-25-9416],[@b6-medscimonit-25-9416]\]. Larger-scale esophageal cancer screening in some countries is delayed, and the relatively low incidence and high cost of screening make it difficult to satisfactorily identify BM in patients with esophageal cancer. Immunocytochemical analysis \[[@b7-medscimonit-25-9416]\] and RT-PCR \[[@b8-medscimonit-25-9416]\] of bone marrow were previously studied to precisely detect metastasis and to predict the survival of patients. 18F-FDG PET(/CT) imaging \[[@b9-medscimonit-25-9416]\] and bone scan \[[@b10-medscimonit-25-9416]\] were also commonly performed for patients with high risk of BM. However, these examinations are invasive and expensive, resulting in higher incidence of iatrogenic injury and increased economic burden. Thus, identification and analyses of risk factors are needed to improve BM screening for patients with esophageal cancer \[[@b11-medscimonit-25-9416]\].

Compared with early-stage cancer patients, the survival of patients with distant metastases is poor. A previous study investigated the association of various metastatic patterns with survival, and found worse survival in patients with BM than in patients with liver metastasis \[[@b12-medscimonit-25-9416]\]. Therefore, it is important to study the prognostic factors for BM patients with esophageal cancer. A previous study reported younger age, poor differentiation, adenoma type, and more distant metastatic sites were significantly correlated with worse prognosis \[[@b5-medscimonit-25-9416]\]. However, these aforementioned studies merely focused on metastases to multiple sites without specially investigating the predictive factors for the prognosis of BM patients with esophageal cancer.

Using data extracting from the Surveillance, Epidemiology, and End Results (SEER) database, we studied the risk and prognostic factors for esophageal cancer patients with initial BM. Common and specific factors for BM occurrence and survival were identified to improve clinical screening and management.

Material and Methods
====================

Data source and cohort selection
--------------------------------

All information used in the present study was derived from the SEER database (*<https://seer.cancer.gov/data/>*), which covers approximately 30% of the population in the USA from 18 registration centers. Due to missing information on metastasis before 2010, we selected patients diagnosed with esophageal cancer between 2010 and 2016 to analyze BM risk factors. Prognostic factors were investigated in a cohort of patients diagnosed from 2010 to 2015 with a follow-up at least for 1 year. Patients were excluded if they were diagnosed via death certificate or at autopsy in this study. [Figure 1](#f1-medscimonit-25-9416){ref-type="fig"} shows the flowchart of inclusion and exclusion of patients.

The SEER database is an open public database, and informed patient consent is not required for extraction of data. The present study complied with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Statistical analysis
--------------------

BM risk factors were studied through univariable and multivariable logistic regression analyses, including the following variables: sex (Male *vs*. Female); age of diagnosis (\<67 years and ≥67 years); race \[white, black, Asian or Pacific Islander (API), and American Indian/Alaska Native (AI)\]; insurance status (uninsured and insured); marital status (unmarried and married); site of primary tumor (upper third including the cervical esophagus, middle third including the thoracic esophagus, and lower third including the abdominal esophagus and overlapping lesion); histological types (esophageal adenocarcinoma \[EAC\], esophageal squamous cell carcinoma \[ESCC\] and others); tumor grade (I, II, III, and IV); T stage (T1, T2, T3, and T4); stage of lymph nodes (N0, N1, N2, and N3); other distant metastatic sites including lung (yes or no), liver (yes or no), and brain (yes or no); and surgical treatment for the primary cancer (yes or no).

The median overall survival (OS) for patients in each category was calculated. Survival duration was obtained by the Kaplan-Meier method, and the log-rank test was used to evaluate difference among curves. Univariable and multivariable Cox hazard regression were performed based on the revealed factors to evaluate the independent factors for prognosis.

Data extraction was performed using the SEER\*Stat Software version 8.3.5, and SPSS 23.0 (IBM Corporation, Armonk, NY, USA) was used to conduct all statistical analyses. MedCalc 15.2.2 was used to generate survival curves. Two-sided *p*-values \<0.05 were considered to be statistically significant.

Results
=======

Patient characteristics
-----------------------

According to the defined inclusion and exclusion criteria, a total of 25 955 patients with esophageal cancer were initially identified from 2010 to 2016, among whom 2075 (8.0%) cases were initially diagnosed with BM. Compared with females, older patients, and other races, more patients with BM were male (N=1,788, 86.2%), younger than 67 years old (N=1178, 56.8%), and white race (N=1778, 85.7%). Regarding the tumor sites, the majority of cancers (58.9%) were located in the lower third of the esophagus. Compared with EAC, the main histological subtype was ESCC (N=1414, 68.1%). According to the AJCC, most patients were diagnosed at grade III (N=1020, 49.2%) and N1 (N=1039, 50.1%). Other distant metastases included 832 patients with liver metastases, 558 with lung metastases, and 146 with brain metastases. Details are shown in [Table 1](#t1-medscimonit-25-9416){ref-type="table"}.

Risk factors for BM
-------------------

Univariable regression identified less BM occurrence in female patients (OR=0.56, 95% CI: 0.49--0.64), older patients (≥67 years *vs*. \<67 years) (OR=0.66, 95% CI: 0.60--0.72), API race (*vs*. white; OR=0.75, 95% CI: 0.59--0.95), and T2 (*vs*. T1; OR=0.51, 95% CI: 0.39--0.65) and T3 (*vs*. T1; OR=0.76, 95% CI: 0.66--0.89). In contrast, risk of BM was higher in patients of AI race (*vs*. white; OR=1.74, 95% CI: 1.13--2.86), middle third (*vs*. upper third; OR=1.70, 95% CI: 1.35--2.16), lower third (*vs*.upper third; OR=1.69, 95% CI: 1.35--2.10), overlapping lesion (*vs*. upper third; OR=2.68, 95% CI: 2.03--3.54), higher tumor grade (II, III and IV *vs*. grade I), higher T stage (T2--T4 *vs*. T1) and N3 stage (*vs*. N0), EAC subtype (*vs*. ESCC; OR=1.53, 95% CI: 1.38--1.70), and patients with metastasis to liver (OR=4.62, 95% CI: 4.20--5.09), lung (OR=4.51, 95% CI: 4.05--5.03), and brain (OR=5.90, 95% CI: 4.82--7.22).

Multivariable analysis further confirmed BM was negatively associated with female sex (OR=0.74, 95% CI: 0.59--0.94), older age (OR=0.81, 95% CI: 0.69--0.95), and higher T stage. More BM was positively associated with grade III (OR=1.66, 95% CI: 1.10--2.50), histological EAC subtype (OR=1.66, 95% CI: 1.30--2.11), higher N stage (N1--N3), and metastasis to liver, lung, and brain. Race, insurance, marital status, and primary site were not independent factors for BM occurrence. More details were provided in [Table 1](#t1-medscimonit-25-9416){ref-type="table"}.

Survival estimation and prognostic factors identification in esophageal cancer patients with BM
-----------------------------------------------------------------------------------------------

A total of 1733 esophageal cancer patients with BM, diagnosed from 2010 to 2015, were extracted to estimate the survival and identify the prognostic factors. Among these patients, only 25 patients received surgical treatment of the primary site ([Table 2](#t2-medscimonit-25-9416){ref-type="table"}). The median OS for all the patients with esophageal cancer was 11 (95% CI: 10.7--11.3) months, and it was decreased to 4 (95% CI 3.7--4.3) months in patients with BM. Kaplan-Meier analysis was performed among esophageal cancer patients diagnosed with initial BM ([Figure 2A](#f2-medscimonit-25-9416){ref-type="fig"}, overall), stratified by sex ([Figure 2B](#f2-medscimonit-25-9416){ref-type="fig"}), age ([Figure 2C](#f2-medscimonit-25-9416){ref-type="fig"}), race ([Figure 2D](#f2-medscimonit-25-9416){ref-type="fig"}), insurance recode ([Figure 2E](#f2-medscimonit-25-9416){ref-type="fig"}), marital status ([Figure 2F](#f2-medscimonit-25-9416){ref-type="fig"}), primary site ([Figure 2G](#f2-medscimonit-25-9416){ref-type="fig"}), grade ([Figure 2H](#f2-medscimonit-25-9416){ref-type="fig"}), histopathologic groups ([Figure 2I](#f2-medscimonit-25-9416){ref-type="fig"}), T stage ([Figure 2J](#f2-medscimonit-25-9416){ref-type="fig"}), N stage ([Figure 2K](#f2-medscimonit-25-9416){ref-type="fig"}), brain metastasis ([Figure 2L](#f2-medscimonit-25-9416){ref-type="fig"}), liver metastasis ([Figure 2M](#f2-medscimonit-25-9416){ref-type="fig"}), lung metastasis ([Figure 2N](#f2-medscimonit-25-9416){ref-type="fig"}), and surgical treatments of the primary site ([Figure 2O](#f2-medscimonit-25-9416){ref-type="fig"}).

Univariable Cox regression analysis suggested improved survival in married patients (HR=0.71, 95% CI: 0.64--0.78), those with insurance (HR=0.62, 95% CI: 0.49--0.78), tumor in the lower third sites (HR=0.78, 95% CI: 0.61--0.99), histological subtype of EAC (HR=0.82, 95% CI: 0.74--0.93), T2 stage (HR=0.59, 95% CI: 0.44--0.79), T3 stage (HR=0.76, 95% CI: 0.65--0.89), and patients after surgery for the primary site (HR=0.56, 95% CI: 0.36--0.86). Patients older than 67 years (HR=1.11, 95% CI: 1.01--1.22), black race (HR=1.22, 95% CI: 1.04--1.44), and with distant metastases to liver (HR=1.22, 95% CI: 1.11--1.35), lung (HR=1.23, 95% CI: 1.10--1.37) and brain (HR=1.37, 95% CI: 1.14--1.66) showed worse OS. Multivariable Cox analysis only confirmed the female, being married, and T2 stage as the protective factors for patients with BM, while T4 stage, brain metastases, and liver metastases were risk factors. More details were given in [Table 2](#t2-medscimonit-25-9416){ref-type="table"}.

Therefore, the homogeneous risk factors for the occurrence and prognosis of BM in esophageal cancer were male, T4 stage, liver metastasis, and brain metastasis. Patients younger than 67 years, grade III, N1--N3, histological subtype of EAC or others, and lung metastases were more likely to have BM occurrence, while unmarried patients were associated with worse survival ([Figure 3](#f3-medscimonit-25-9416){ref-type="fig"}).

Discussion
==========

In the present study, large-population-based research was conducted to thoroughly study the risk and prognostic factors for initial BM in esophageal cancer. Results suggested 8.0% of patients with esophageal cancer were diagnosed with initial BM. Limited by the weakness of BM precise detection in the early stage without significant symptoms, the actual BM incidence in esophageal cancer patients may be underestimated.

Investigating the risk factors was important for identifying patients at high risk for distant metastases \[[@b13-medscimonit-25-9416],[@b14-medscimonit-25-9416]\] Results in our study revealed that patients with age younger than 67 years, male sex, T4 stage grade III, N1--3, histological subtype of EAC or others, and metastasis to liver, lung, and brain were more likely to have BM. These revealed risk factors can guide the identification of esophageal cancer patients with high risk of developing BM. A previous study showed that a missed preoperative bone scan was independently associated with poor survival \[[@b10-medscimonit-25-9416]\]. Thus, bone scans should be recommended for patients with high risk of metastasis. Furthermore, the revealed risk factors could be used to establish an initial BM prediction system in esophageal cancer.

Early diagnosis and timely treatment are crucial to improve the survival of cancer patients. Distant metastases, including liver, lung, and bone, in the advanced stages significantly reduces life expectancy \[[@b15-medscimonit-25-9416]\]. Thus, identification of predictive prognostic factors is important in clinical cancer management. Previous studies described patterns of distant metastases in esophageal cancer and reported worse survival in male patients \[[@b16-medscimonit-25-9416]\], unmarried patients \[[@b17-medscimonit-25-9416]\], black patients and racial difference for surgery \[[@b18-medscimonit-25-9416]\]. In this study, we further confirmed the females, married patients, and T2 stage are protective factor for BM, while T4 stage, brain metastases, and liver metastases as the risk factors for BM. Surgery was only performed in 25 patients in the cohort, making it difficult to evaluate the real effect of surgery on survival. All these aforementioned prognostic factors can be applied to tailor the individualized treatment regimen and improve patient survival.

EAC and ESCC were the 2 major types of esophageal cancer. Previous studies showed different risk factors and incidence patterns \[[@b19-medscimonit-25-9416]\], metastatic patterns, and higher male-to-female ratio for BM incidence in different types \[[@b20-medscimonit-25-9416]\]. In our study, we found more BM occurrence in EAC, but a trend of better survival, although the difference was not statistically significant. Regarding the different origination, main causes, and location for ESCC and EAC \[[@b20-medscimonit-25-9416],[@b21-medscimonit-25-9416]\], further research is needed to compare metastatic behavior and survival between these 2 types of esophageal cancer.

Bone is one of the most common metastatic sites for a number of solid tumors. A series of resident cells in bone form the complex tissue and participate in bone functions. Osteoblasts and osteoclasts play major roles in bone remodeling \[[@b22-medscimonit-25-9416]\]. To meet the various needs of the host, bone physiology can be regulated through osteoblasts and osteoclasts \[[@b23-medscimonit-25-9416]\]. However, solid tumors can disrupt the delicate balance of bone physiology and result in an environment that promotes metastasis \[[@b24-medscimonit-25-9416]\]. Recent studies reported the diverse homogeneous and heterogeneous associated factors in cancers correlated with bone metastasis \[[@b3-medscimonit-25-9416],[@b4-medscimonit-25-9416],[@b13-medscimonit-25-9416],[@b14-medscimonit-25-9416]\]. Few studies have assessed the correlation between bone homeostasis and esophageal cancer, and further research is needed to identify the underlying mechanism.

Currently, there has been no clear screening guide for BM in cancers. For the diagnosis of BM, based on different imaging systems, 5 main imaging strategies are accepted: PET-CT, bone scintigraphy, MRI, CT, and X-ray. In a recent study on prostate cancer patients with BM, PET-CT was proved to have the highest per-patient sensitivity and specificity in detecting BM \[[@b25-medscimonit-25-9416]\]. Bone scintigraphy has the advantage of being considerably cheaper than PET-CT. A recent study suggested bone scintigraphy combined with parallelepiped classification method could play an important role in the detection of BM, allowing for an easier but correct interpretation of the images \[[@b26-medscimonit-25-9416]\]. MRI, CT, and X-ray can be applied for the detection of the specific metastatic site. Undoubtedly, with the development of BM diagnostic research, a detailed BM screening guide will be needed.

Based on the largest cohort from the SEER database, we identified homogeneous and heterogeneous factors for initial BM in esophageal cancer patients. Our study has certain limitations that should be mentioned to better interpret the findings. Many important factors, such as region, environment, and genetic characteristics, were not available in the SEER database. Only patients with synchronous diagnosis of cancer and BM are available in the SEER database, making it impossible to evaluate the effect of interval from initial cancer to BM development on survival. Detail types of BM cannot be assessed, resulting in bias in survival evaluation. More information on treatment, including chemotherapy, radiotherapy, and surgery, are needed to evaluate their effects on patient survival.

Conclusions
===========

Using the data from the SEER database, we found that the incidence of initial BM in esophageal cancer patients was approximately 8.0%. A series of risk factors for occurrence of BM were found, in which BM was negatively associated with female sex, older age, and higher T stage. More BM was positively associated with grade III, histological EAC subtype, higher N stage, and metastasis to liver, lung, and brain. We also found prognostic factors for BM patient survival in esophageal cancer. Female sex, being married, and T2 stage were the protective factors for survival of BM patients, while T4 stage, brain metastases, and liver metastases were risk factors. Individual assessment and prediction can be performed based on these independent factors, especially the homogeneous factors.
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###### 

Logistic regression for characteristics to develop initial BM in patients with primary esophageal cancer (diagnosed 2010--2016).

  Subject characteristics   No. of esophageal cancer patients   Univariable   Multivariable                                                                          
  ------------------------- ----------------------------------- ------------- --------------- ---------- --------- ------------------- --------- ------------------- ---------
  Sex                                                                                         79.113     \<0.001                                                     
   Male                     1788                                20 367        8.78                                 1.00 (Reference)              1.00 (Reference)    
   Female                   287                                 5588          5.14                                 0.56 (0.49--0.64)   \<0.001   0.74 (0.59--0.94)   0.012
  Age                                                                                         82.546     \<0.001                                                     
   \<67                     1178                                12 256        9.61                                 1.00 (Reference)              1.00 (Reference)    
   ≥67                      897                                 13 699        6.55                                 0.66 (0.60--0.72)   \<0.001   0.81 (0.69--0.95)   0.010
  Race                                                                                        18.696     0.001                                                       
   White                    1778                                21 889        8.12                                 1.00 (Reference)              1.00 (Reference)    
   Black                    198                                 2605          7.60                                 0.93 (0.80--1.08)   0.355     1.21 (0.90--1.62)   0.215
   AI                       24                                  180           13.33                                1.74 (1.13--2.68)   0.012     0.93 (0.39--2.26)   0.878
   API                      74                                  1196          6.19                                 0.75 (0.59--0.95)   0.017     1.00 (0.67--1.50)   0.996
   Unknown                  1                                   85            1.18                                 NA                  NA        NA                  NA
  Insurance recode                                                                            6.946      0.031                                                       
   Uninsured                80                                  760           10.53                                1.00 (Reference)              1.00 (Reference)    
   Insured                  1944                                24 520        7.93                                 0.73 (0.58--0.93)   0.010     1.25 (0.79--1.98)   0.349
   Unknown                  51                                  675           7.56                                 NA                  NA        NA                  NA
  Marital status                                                                              4.784      0.091                                                       
   Unmarried                854                                 10 550        8.09                                 1.00 (Reference)              NA                  NA
   Married                  1,126                               13,941        8.08                                 1.00 (0.91--1.09)   0.959     NA                  NA
   Unknown                  95                                  1464          6.49                                 NA                  NA        NA                  NA
  Primary site                                                                                82.019     \<0.001                                                     
   Upper third              91                                  1922          4.73                                 1.00 (Reference)              1.00 (Reference)    
   Middle third             379                                 4854          7.81                                 1.70 (1.35--2.16)   \<0.001   1.28 (0.86--1.90)   0.228
   Lower third              1223                                15 821        7.73                                 1.69 (1.35--2.10)   \<0.001   0.84 (0.56--1.26)   0.407
   Overlapping lesion       133                                 1132          11.75                                2.68 (2.03--3.54)   \<0.001   0.98 (0.59--1.63)   0.946
   Unknown                  249                                 2226          11.19                                NA                  NA        NA                  NA
  Grade                                                                                       129.251    \<0.001                                                     
   Grade I                  48                                  1255          3.82                                 1.00 (Reference)    1.00      1.00 (Reference)    1.00
   Grade II                 502                                 8461          5.93                                 1.59 (1.17--2.15)   0.003     1.08 (0.71--1.64)   0.711
   Grade III                1020                                10 396        9.81                                 2.74 (2.04--3.68)   \<0.001   1.66 (1.10--2.50)   0.015
   Grade IV                 33                                  335           9.85                                 2.75 (1.73--4.36)   \<0.001   1.55 (0.73--3.31)   0.255
   Unknown                  472                                 5508          8.57                                 NA                  NA        NA                  NA
  Histology                                                                                   87.047     \<0.001                                                     
   ESCC                     494                                 8366          5.90                                 1.00 (Reference)              1.00 (Reference)    
   EAC                      1414                                16 108        8.78                                 1.53 (1.38--1.70)   \<0.001   1.66 (1.30--2.11)   \<0.001
   Others                   55                                  425           12.94                                2.37 (1.76--3.19)   \<0.001   1.99 (1.06--3.71)   0.031
   Unknown                  112                                 1056          10.61                                NA                  NA        NA                  NA
  T stage                                                                                     822.064    \<0.001                                                     
   T1                       369                                 6525          5.66                                 1.00 (Reference)              1.00 (Reference)    
   T2                       73                                  2477          2.95                                 0.51 (0.39--0.65)   \<0.001   0.58 (0.42--0.79)   0.001
   T3                       355                                 8099          4.38                                 0.76 (0.66--0.89)   \<0.001   0.65 (0.53--0.81)   \<0.001
   T4                       325                                 2803          11.59                                2.19 (1.87--2.56)   \<0.001   1.24 (1.00--1.55)   0.053
   Unknown                  953                                 6051          15.75                                NA                  NA        NA                  NA
  N stage                                                                                     385.480    \<0.001                                                     
   N0                       466                                 10 596        4.40                                 1.00 (Reference)              1.00 (Reference)    
   N1                       1039                                9879          10.52                                2.55 (2.28--2.86)   \<0.001   1.96 (1.60--2.39)   \<0.001
   N2                       169                                 2,429         6.96                                 1.63 (1.36--1.95)   \<0.001   2.00 (1.51--2.64)   \<0.001
   N3                       125                                 931           13.43                                3.37 (2.73--4.16)   \<0.001   2.97 (2.14--4.12)   \<0.001
   Unknown                  276                                 2120          13.02                                NA                  NA        NA                  NA
  Brain metastases                                                                            769.394    \<0.001                                                     
   None                     1859                                25 373        7.33                                 1.00 (Reference)              1.00 (Reference)    
   Yes                      146                                 459           31.81                                5.90 (4.82--7.22)   \<0.001   3.21 (2.15--4.79)   \<0.001
   Unknown                  70                                  123           56.91                                NA                  NA        NA                  NA
  Liver metastases                                                                            1278.829   \<0.001                                                     
   None                     1191                                21 863        5.45                                 1.00 (Reference)              1.00 (Reference)    
   Yes                      832                                 3958          21.02                                4.62 (4.20--5.09)   \<0.001   3.56 (2.96--4.29)   \<0.001
   Unknown                  52                                  134           38.81                                NA                  NA        NA                  NA
  Lung metastases                                                                             1083.907   \<0.001                                                     
   None                     1429                                23 254        6.15                                 1.00 (Reference)              1.00 (Reference)    
   Yes                      558                                 2448          22.79                                4.51 (4.05--5.03)   \<0.001   2.73 (2.21--3.37)   \<0.001
   Unknown                  88                                  253           34.78                                NA                  NA        NA                  NA

BM -- bone metastasis; AI -- American Indian/Alaska Native; API -- Asian or Pacific Islander; ESCC -- esophageal squamous cell carcinoma; EAC -- esophageal adenocarcinoma; Met -- metastases; OR -- odds ratio; CI -- confidence interval.

###### 

Cox regression for analyzing the mortality among BM patients in primary esophageal cancer (diagnosed 2010--2015).

  Subject characteristics   No. of patients with BM   Survival, median (IQR), mo   Univariable       Multivariable                                     
  ------------------------- ------------------------- ---------------------------- ----------------- ------------------- --------- ------------------- -------
  Sex                                                                                                                                                  
   Male                     1488                      1439 (96.71)                 4 (3.68--4.32)    1.00 (Reference)              1.00 (Reference)    
   Female                   245                       233 (95.10)                  4 (3.29--4.71)    0.92 (0.80--1.06)   0.229     0.77 (0.60--0.99)   0.043
  Age                                                                                                                                                  
   \<67                     987                       951 (96.35)                  4 (3.56--4.44)    1.00 (Reference)              1.00 (Reference)    
   ≥67                      746                       721 (96.65)                  3 (2.63--3.37)    1.11 (1.01--1.22)   0.033     1.18 (0.99--1.40)   0.060
  Race                                                                                                                                                 
   White                    1492                      1435 (96.18)                 4 (3.68--4.32)    1.00 (Reference)              1.00 (Reference)    
   Black                    161                       161 (100.00)                 3 (2.41--3.59)    1.22 (1.04--1.44)   0.017     1.10 (0.79--1.53)   0.575
   AI                       17                        17 (100.00)                  3 (0.58--5.42)    1.23 (0.76--1.98)   0.398     0.91 (0.37--2.23)   0.840
   API                      63                        59 (93.65)                   3 (1.60--4.40)    1.03 (0.79--1.34)   0.816     0.94 (0.61--1.44)   0.777
   Unknown                                                                         NA                NA                  NA        NA                  NA
  Insurance recode                                                                                                                                     
   Uninsured                72                        72 (100.00)                  1 (0.38--1.62)    1.00 (Reference)              1.00 (Reference)    
   Insured                  1615                      1554 (96.22)                 4 (3.70--4.30)    0.62 (0.49--0.78)   \<0.001   0.65 (0.41--1.04)   0.071
   Unknown                  46                        46 (100.00)                  NA                NA                  NA        NA                  NA
  Marital status                                                                                                                                       
   Unmarried                704                       689 (97.87)                  3 (2.68--3.32)    1.00 (Reference)              1.00 (Reference)    
   Married                  947                       903 (95.35)                  5 (4.57--5.43)    0.71 (0.64--0.78)   \<0.001   0.79 (0.66--0.94)   0.009
   Unknown                  82                        80 (97.56)                   NA                NA                  NA        NA                  NA
  Primary site                                                                                                                                         
   Upper third              74                        73 (98.65)                   3 (1.60--4.40)    1.00 (Reference)              1.00 (Reference)    
   Middle third             325                       315 (96.92)                  4 (3.36--4.64)    0.87 (0.67--1.12)   0.274     0.76 (0.50--1.15)   0.193
   Lower third              1009                      973 (96.43)                  4 (3.53--4.47)    0.78 (0.61--0.99)   0.039     0.85 (0.56--1.29)   0.441
   Overlapping lesion       107                       102 (95.33)                  2 (1.03--2.97)    1.02 (0.75--1.38)   0.903     1.10 (0.64--1.88)   0.731
   Unknown                  218                       209 (95.87)                  NA                NA                  NA        NA                  NA
  Grade                                                                                                                                                
   Grade I                  42                        38 (90.48)                   6 (2.82--9.18)    1.00 (Reference)              1.00 (Reference)    
   Grade II                 415                       399 (96.14)                  5 (4.29--5.71)    1.30 (0.93--1.82)   0.120     0.96 (0.61--1.49)   0.849
   Grade III                854                       826 (96.72)                  3 (2.59--3.41)    1.61 (1.16--2.23)   0.004     1.14 (0.73--1.76)   0.565
   Grade IV                 27                        27 (100.00)                  4 (1.96--6.04)    1.40 (0.85--2.31)   0.184     1.98 (0.92--4.29)   0.082
   Unknown                  395                       382 (96.71)                  NA                NA                  NA        NA                  NA
  Histology                                                                                                                                            
   ESCC                     409                       396 (96.82)                  3 (2.52--3.48)    1.00 (Reference)              1.00 (Reference)    
   EAC                      1179                      1132 (96.01)                 4 (3.58--4.42)    0.82 (0.74--0.93)   0.001     0.79 (0.61--1.01)   0.061
   Others                   45                        45 (100.00)                  2 (0.54--3.46)    0.99 (0.73--1.34)   0.934     0.66 (0.36--1.22)   0.181
   Unknown                  100                       99 (99.00)                   NA                NA                  NA        NA                  NA
  T stage                                                                                                                                              
   T1                       349                       337 (96.56)                  4 (3.44--4.56)    1.00 (Reference)              1.00 (Reference)    
   T2                       58                        52 (89.66)                   7 (4.51--9.49)    0.59 (0.44--0.79)   \<0.001   0.52 (0.35--0.76)   0.001
   T3                       294                       279 (94.90)                  6 (5.10--6.90)    0.76 (0.65--0.89)   0.001     0.82 (0.66--1.01)   0.060
   T4                       275                       269 (97.82)                  3 (2.39--3.61)    1.15 (0.98--1.35)   0.085     1.27 (1.01--1.59)   0.039
   Unknown                  757                       735 (97.09)                  NA                NA                  NA        NA                  NA
  N stage                                                                                                                                              
   N0                       391                       380 (97.19)                  3 (2.40--3.60)    1.00 (Reference)              1.00 (Reference)    
   N1                       913                       881 (96.50)                  4 (3.54--4.46)    0.93 (0.83--1.05)   0.242     0.93 (0.75--1.14)   0.475
   N2                       123                       118 (95.93)                  5 (3.88--6.12)    0.83 (0.68--1.03)   0.085     1.08 (0.79--1.47)   0.641
   N3                       89                        80 (89.89)                   3 (1.32--4.68)    0.90 (0.71--1.15)   0.399     1.16 (0.82--1.66)   0.404
   Unknown                  217                       213 (98.16)                  NA                NA                  NA        NA                  NA
  Brain metastases                                                                                                                                     
   None                     1550                      1495 (96.45)                 4 (3.68--4.32)    1.00 (Reference)              1.00 (Reference)    
   Yes                      122                       118 (96.72)                  3 (2.26--3.74)    1.37 (1.14--1.66)   0.001     1.76 (1.24--2.51)   0.002
   Unknown                  61                        59 (96.72)                   NA                NA                  NA        NA                  NA
  Liver metastases                                                                                                                                     
   None                     1011                      971 (96.04)                  4 (3.55--4.45)    1.00 (Reference)              1.00 (Reference)    
   Yes                      672                       652 (97.02)                  3 (2.59--3.41)    1.22 (1.11--1.35)   \<0.001   1.24 (1.04--1.48)   0.015
   Unknown                  50                        49 (98.00)                   NA                NA                  NA        NA                  NA
  Lung metastases                                                                                                                                      
   None                     1187                      1141 (96.12)                 4 (3.60--4.40)    1.00 (Reference)              1.00 (Reference)    
   Yes                      465                       451 (96.99)                  3 (2.56--3.44)    1.23 (1.10--1.37)   \<0.001   1.16 (0.95--1.42)   0.140
   Unknown                  81                        80 (98.77)                   NA                NA                  NA        NA                  NA
  Surg (prim)                                                                                                                                          
   None                     1706                      1649 (96.66)                 4 (3.70--4.30)    1.00 (Reference)              1.00 (Reference)    
   Yes                      25                        21 (84.00)                   8 (3.10--12.90)   0.56 (0.36--0.86)   0.009     0.57 (0.31--1.08)   0.084
   Unknown                  2                         2 (100.00)                   NA                NA                  NA        NA                  NA

BM -- bone metastasis; AI -- American Indian/Alaska Native; API -- Asian or Pacific Islander; ESCC -- esophageal squamous cell carcinoma; EAC -- esophageal adenocarcinoma; Met -- metastases; Surg (prim) -- surgical treatment of primary site; HR -- hazard ratio; CI -- confidence interval.
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